Alerta

METHODS FOR IDENTIFYING AND TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: WO2026050646A1

This disclosure concerns metabolites that can be used to identify and characterize inflammatory bowel disease (IBD) as well as assess treatment for IBD.

Nano-enzyme coating recombinant probiotics as well as preparation method and application thereof

Resumen de: CN121592569A

The invention discloses nano-enzyme coating recombinant probiotics as well as a preparation method and application thereof, and belongs to the technical field of biotechnology and nano medicine. According to the invention, engineered Escherichia coli Nissle 1917 (ECN (DE3)) is taken as a host, and glutathione peroxidase (GPX) and glutathione reductase (GR) genes are over-expressed through a genetic engineering means, so that an efficient antioxidant enzyme system is constructed. And sequentially modifying chitosan and cerium dioxide nano-enzyme (CNP) on the surfaces of the thalli by using an electrostatic layer-by-layer self-assembly technology to form a protective coating. The nano-enzyme coating significantly improves the survival rate of the recombinant probiotics in severe environments such as simulated gastric acid (pH 2.5) and bile salt (0.3%), and enhances the ability of the recombinant probiotics to remove reactive oxygen species (ROS), including hydrogen peroxide, superoxide anions, hydroxyl free radicals and DPPH free radicals.

Ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using Re-SILEX technology

Resumen de: CN121592655A

The invention discloses a method for screening an ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using a Re-SILEX technology, and belongs to the technical field of nucleic acid. The invention aims to solve the technical problem of how to effectively detect or target CD4 protein. In order to solve the technical problem, the invention provides a nucleic acid aptamer, the nucleic acid aptamer is at least one of nucleic acid aptamers with the name of CD4rzj-4a, CD4rzj-2a, CD4rzj-5a, CD4rzj-6a, CD4rzj-1b, CD4rzj-3a and CD4rzj-1a, and the nucleic acid aptamer CD4rzj-4a is a nucleic acid molecule with the nucleotide sequence of SEQ ID NO: 6. The aptamer provided by the invention has excellent specific binding force, and has important application potential in the field of CD4 detection or targeting.

METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

A METHOD OF IMMUNE MODULATION BY MODULATING ABCF1

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

USE OF RIFAXIMIN IN SUBJECTS HAVING DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

Application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases

Resumen de: CN121570596A

The invention relates to the technical field of biological medicines, in particular to application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases. The invention provides an application of a substance for inhibiting the activity of RNF219 protein or a substance for reducing the content of RNF219 protein in preparation of drugs for preventing or treating inflammatory diseases, especially drugs for preventing or treating sepsis and colitis. According to the application, a mouse acute infection model is constructed to prove that RNF219 defect inhibits the inflammatory reaction degree and inflammatory injury induced by LPS (Lipopolysaccharide); in a mouse with DSS-induced colitis, the RNF219 defect can delay the disease progress of the mouse colitis and improve the inflammatory phenotype of the mouse. Therefore, the function of the RNF219 in natural immune response is defined, and the RNF219 has important scientific significance on prevention and treatment of immune inflammation related diseases such as sepsis and inflammatory bowel diseases.

基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用

Resumen de: CN121575078A

本发明涉及生物医学工程，公开了一种基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用。该筛选方法包括以下步骤：采用表面经仿生化处理的超表面等离子共振生物芯片，进行肠壁细胞培养或者小胶质细胞培养获得肠壁细胞贴壁或者小胶质细胞贴壁的芯片板，在细胞贴壁的芯片板内加入含化疗药物或脂多糖的培养基进行培养I，再除去培养基、加入待测治疗剂进行培养II得到培养液，检测所述培养液中肠壁细胞或者小胶质细胞的细胞修复效果；筛选获得对肠壁细胞和/或小胶质细胞具有修复作用的治疗剂。该筛选方法能够从多个待测治疗剂中高效、准确地筛选出兼具肠道调节与神经保护双重功效的治疗剂，且能够实现无标记、实时在线动态监测与探究治疗剂和细胞的相互作用情况。

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Resumen de: US20260055183A1

Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.

METHOD, PROGRAM, AND APPARATUS FOR DETECTING SMALL INTESTINAL BACTERIAL OVERGROWTH

Resumen de: US20260053426A1

Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.

SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPIES

Resumen de: US20260057960A1

Disclosed herein are methods and systems for administering therapy to subjects who have been determined to display or not display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the therapy. The subject and prior subjects may suffer from a disease, disorder, or condition for which it is desired to predict whether the subject will respond to the therapy. In an aspect, the disease, disorder, or condition may be an autoimmune disorder such as ulcerative colitis. The subject may be administered an anti-TNF therapy or an alternative to anti-TNF therapy based upon predictions provided by methods and systems described herein.

PREDICTING NON-RESPONSIVENESS OF IBD PATIENTS

Nº publicación: EP4698905A1 25/02/2026

Solicitante:

NAVOLAB DIAGNOSZTIKA KFT [HU]
Navolab Diagnosztika Kft.

Resumen de: WO2024224133A1

Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.